Recent Updates
Recently added Catalysts

Gossamer Bio, Inc.

GOSSFDA catalysts, PDUFA dates & pipeline intelligence
$11.04
▲ +0.06 · +0.55%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full GOSS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $8.2952W HIGH $309.60
Volume
221.75 K
Value Traded
2.39 M
Short % Float
23.87%
Days to Cover
7.5
-5.56%Week
+30.96%1 Month
-11.88%3 Month
-35.9%6 Month
-97.75%5 Year
-98.89%All Time

Cash Data

Unlock GOSS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
67.52 M
EPS (TTM)
-20.45
P/E Ratio
-
Ent. Value
16.34 M
Total Shares
6.12 M
Float Shares
5.61 M
Insiders
8.34%
Institutions
69.82%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Approval Decision
seralutinib (GB002)
pulmonary arterial hypertension (PAH)
NDASmall MoleculesCardiovascular
Unlock every GOSS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

GOSS Catalyst Timeline

Dated clinical, regulatory and corporate events for Gossamer Bio, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Gossamer Bio, Inc.

214Total events
9Upcoming
55Tier-1 (high impact)
2018 to 2028Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
SeralutinibFiled
T1PDUFA Date
Subscribe to view catalyst details
SeralutinibFiled

Event history 50

●Quarterly UpdateCorporate
Third quarter 2026 financial results and business update
●Management ChangeCorporate
Greg Ciongoli appointed to Gossamer Bio Board of Directors
●Reverse Stock SplitCorporate
Common stock expected to begin trading on split-adjusted basis on Nasdaq
▼Reverse Stock SplitCorporate
1-for-80 reverse stock split became effective
●Reverse Stock SplitCorporate
Board selects 1-for-80 reverse stock split ratio
●NDA SubmissionSeralutinibFiledRegulatory Filing
NDA submitted to FDA for seralutinib in PAH
pulmonary arterial hypertension (PAH)source ↗
◆Timing GuidanceSeralutinibFiledPresentation
Planned NDA submission for seralutinib in PAH
pulmonary arterial hypertension (PAH)source ↗
▼Reverse Stock SplitCorporate
1-for-80 reverse stock split completed to regain Nasdaq compliance
◆Equity OfferingCorporate
Private placement financing with up to $250 million gross proceeds
▼Equity OfferingCorporate
Private placement financing with up to $250 million gross proceeds
Unlock the full GOSS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How GOSS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30seralutinib (GB002) NDA Submission NDA
Unlock 7 more GOSS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 58%
Micro Cap
(rank 421 of 725)
Percentile Rank
Showing 4 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Seralutinib Small MoleculesNCT03926793Pulmonary Arterial HypertensionPhase 3 COMPLETED 728May 5, 2021
Seralutinib Small MoleculesCompletedNCT04456998Pulmonary Artery HypertensionPhase 2 COMPLETED 86Nov 1, 2022
Seralutinib Small MoleculesCompletedNCT03473236Safety IssuesPhase 1 COMPLETED 66Dec 3, 2018
GB004 Small MoleculesCompletedNCT03860896Ulcerative ColitisPhase 1 COMPLETED 34Dec 17, 2019
Unlock the GOSS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every GOSS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Gossamer Bio Phase 32026-05-07failed to meet the primary endpointRead MoreGOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallStRead More
Scroll for more · summaries link to the source press release
Unlock every GOSS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock GOSS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Aranda RichardOfficer (Chief Medical Officer)Disposition -562,500 $0.00 03/19/2026
Unlock the full GOSS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Opaleye Management Inc. 0.6 % (-45.5 %) 5.06 M 426.99 K -84.3% ( -2.29 M)
Unlock every fund holding GOSS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in GOSS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see GOSS ownership
Insider and institutional ownership, quarter by quarter.

GOSS Short Interest

Shares sold short, counted twice a month.

23.87%
Short % of Float
of tradable shares sold short
1.3M
Shares Sold Short
-6.8% vs prior count
7.5 High
Days to Cover
trading days of normal volume to buy every short share back
178.1K
Avg Daily Volume
the average used for days to cover
Unlock GOSS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock GOSS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live GOSS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock GOSS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How GOSS ranks across every disease it competes in

Competitive Position is a premium feature
See how GOSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

GOSS News

GOSS
Nov 10, 2026
GOSSFDA Updates

Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio reported its third quarter 2026 financial results, highlighting the submission of its first New Drug Application (NDA) for seralutinib to the FDA for pulmonary arterial hypertension. The company secured $25 million upfront from a structured private placement, with potential for an additional $125 million upon FDA acceptance. Gossamer also completed a reverse stock split to comply with Nasdaq requirements.

Read more →
GOSS
Sep 23, 2026
GOSSFDA Updates

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio has submitted a New Drug Application to the U.S. FDA for seralutinib, aimed at treating pulmonary arterial hypertension (PAH). This marks a significant step in the drug's development and potential commercialization. The application reflects the company's commitment to addressing serious health conditions associated with pulmonary hypertension.

Read more →
GOSS
Sep 16, 2026
GOSSGeneral
▲ +8.9%on this news

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Gossamer Bio has appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026. Ciongoli will also be a member of the Audit Committee. This appointment is expected to enhance the company's leadership and governance as it focuses on developing treatments for pulmonary arterial hypertension and related conditions.

Read more →
GOSS
Sep 11, 2026
GOSSGeneral
▼ -5.8%on this newsshared move

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split to enhance its stock structure. The company has filed a Certificate of Amendment with the Delaware Secretary of State. This move is aimed at improving market perception and potentially attracting more institutional investors.

Read more →
GOSS
Sep 9, 2026
GOSSGeneral
▼ -11.2%on this news· ran to -26% by day 3shared move

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split of its common stock, which is intended to reduce the number of outstanding shares. This decision comes amid the company's focus on developing seralutinib for pulmonary arterial hypertension. The board aims to enhance the stock's marketability and align it with compliance requirements.

Read more →
GOSS
Sep 4, 2026
GOSSConferences/Events

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer Bio, Inc. will present at the Cantor Global Healthcare Conference from September 9-11, 2026. The presentation will focus on their clinical-stage product, seralutinib, aimed at treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This event is expected to boost the company's visibility in the healthcare sector.

Read more →
GOSS
Aug 21, 2026
GOSSFDA Updates

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio has announced a significant private placement financing of up to $250 million, which includes $150 million in committed capital. This funding is intended to support the development of seralutinib, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, as it progresses towards potential FDA approval.

Read more →
GOSS
Aug 13, 2026
GOSSGeneral
▼ -9.5%on this news

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio, a clinical-stage biopharmaceutical firm, announced its financial results for the second quarter of 2026. The company is focused on developing seralutinib for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The update reflects Gossamer's ongoing efforts to strengthen its business.

Read more →
GOSS
Jul 27, 2026
GOSSFDA Updates
▲ +46.6%on this news

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Gossamer Bio has announced significant regulatory and corporate updates, including positive feedback from the FDA following a Pre-NDA Type B meeting. The company has also reacquired worldwide rights to seralutinib, which is intended for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. These developments signal a promising direction for Gossamer's future in the biopharmaceutical market.

Read more →
GOSS
Jul 1, 2026
GOSSGeneral

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Gossamer Bio, Inc. has announced the conversion rate for its 7.50% convertible senior secured first lien notes due in 2030, along with the exercise price for purchase warrants. This announcement is part of the company's ongoing financial strategy. Further details regarding the implications of these changes were not provided in the article.

Read more →
GOSS
Jun 17, 2026
GOSSGeneral
▲ +6.7%on this news

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. has announced the final tender results for its exchange offer and consent solicitation concerning existing convertible notes. The announcement provides details about the completion of the exchange offer, but lacks specific financial figures or implications for stakeholders. The company aims to streamline its capital structure through this initiative.

Read more →
GOSS
Jun 3, 2026
GOSSGeneral
▼ -5.9%on this news· ran to -17% by day 3

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. has announced the early tender results and early settlement for its exchange offer and consent solicitation related to existing convertible notes. The announcement indicates a strategic move by the company but lacks detailed information on the implications or outcomes of the offer.

Read more →
GOSS
Jun 2, 2026
GOSSGeneral

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. has announced an extension of the early tender date for its exchange offer and consent solicitation related to existing convertible notes. This decision is part of the company's ongoing financial strategies. Further details regarding the implications of this extension were not provided in the announcement.

Read more →
GOSS
May 18, 2026
GOSSGeneral
▼ -43.3%on this news

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio has released its financial results for the first quarter of 2026 along with a business update. The details of the financial performance and any strategic plans or developments were not disclosed in the article. Further insights into the company's direction or upcoming initiatives were also not provided.

Read more →
GOSS
May 18, 2026
GOSSGeneral
▼ -43.3%on this news

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio, Inc. has announced an exchange offer and consent solicitation aimed at eliminating over $120 million of debt. This initiative has received support from existing noteholders, indicating confidence in the company's financial strategy. The move is part of Gossamer's efforts to strengthen its balance sheet and improve financial stability.

Read more →
GOSS
May 15, 2026
GOSSConferences/Events

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Gossamer Bio has scheduled the announcement of its first quarter 2026 financial results. The company will host a conference call and webcast on May 18, 2026, to discuss the results. Further details regarding the financial performance and future outlook may be shared during this event.

Read more →
GOSS
Mar 17, 2026
GOSSGeneral

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Gossamer Bio reported its financial results for Q4 and full-year 2025, highlighting the performance of seralutinib in treating pulmonary arterial hypertension (PAH). Despite missing the primary endpoint in the PROSERA study, the company noted significant improvements in certain patient subgroups. Gossamer plans to engage with the FDA regarding future regulatory strategies while managing operational costs.

Read more →
GOSS
Feb 23, 2026
GOSSPhases
▼ -80.1%on this newsshared move

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Gossamer Bio announced topline results from the Phase 3 PROSERA Study of seralutinib for pulmonary arterial hypertension (PAH). Although the primary endpoint did not meet the stringent statistical threshold, seralutinib demonstrated significant improvements in six-minute walk distance (6MWD) and showed efficacy in high-risk patient subgroups. The company plans to discuss these results with the FDA for potential next steps.

Read more →
GOSS
Jan 9, 2026
GOSSGeneral

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026

Gossamer Bio has announced the approval of stock option grants to three non-executive employees as part of its 2023 Employment Inducement Incentive Award Plan. The grants, effective January 5, 2026, allow for the purchase of up to 212,500 shares at an exercise price of $2.74 each. This initiative aims to attract and retain talent while supporting the company's focus on developing treatments for pulmonary hypertension.

Read more →
GOSS
Nov 5, 2025
GOSSPhases

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio reported its financial results for Q3 2025, highlighting a cash position of $180 million and the activation of the first site for its Phase 3 SERANATA study in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company anticipates topline results from the ongoing PROSERA Phase 3 study by February 2026. Despite the positive developments, Gossamer recorded a net loss of $48.2 million for the quarter, raising concerns over rising research and development expenses. The firm emphasizes its commitment to addressing unmet medical needs in pulmonary hypertension, supported by ongoing collaborations and community engagement.

Read more →

About Gossamer Bio, Inc.

San Diego, CA 162 employees gossamerbio.com
Headquarters3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE
Trade the next GOSS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime